Journal ArticleDOI
Tissue plasminogen activator for the treatment of thromboembolism in infants and children
Maurice Levy,Lee N. Benson,Patricia E. Burrows,Yedidia Bentur,Dawn K Strong,Joanne Smith,David W. Johnson,Sheila Jacobson,Gideon Koren +8 more
TLDR
It is concluded that tissue plasminogen activator is effective in inducing clot lysis in children and it is recommended that a dose of 0.1 mg/kg per hour be started and increased gradually if clot dissolution does not occur, with close monitoring for bleeding.About:
This article is published in The Journal of Pediatrics.The article was published on 1991-03-01. It has received 118 citations till now. The article focuses on the topics: Tissue plasminogen activator.read more
Citations
More filters
Journal ArticleDOI
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease A Statement for Health Professionals From the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association
Jane W. Newburger,Masato Takahashi,Michael A. Gerber,Michael H. Gewitz,Lloyd Y. Tani,Jane C. Burns,Stanford T. Shulman,Ann F. Bolger,Patricia Ferrieri,Robert S. Baltimore,Walter R. Wilson,Larry M. Baddour,Matthew E. Levison,Thomas J. Pallasch,Donald A. Falace,Kathryn A. Taubert +15 more
TL;DR: Recommendations for the initial evaluation, treatment in the acute phase, and long-term management of patients with Kawasaki disease are intended to assist physicians in understanding the range of acceptable approaches for caring for patients withawasaki disease.
Journal ArticleDOI
Diagnosis, treatment, and long-term management of Kawasaki disease: A statement for health professionals from the committee on rheumatic fever, endocarditis, and Kawasaki disease, council on cardiovascular disease in the young, American Heart Association
Jane W. Newburger,Masato Takahashi,Michael A. Gerber,Michael H. Gewitz,Lloyd Y. Tani,Jane C. Burns,Stanford T. Shulman,Ann F. Bolger,Patricia Ferrieri,Robert S. Baltimore,Walter R. Wilson,Larry M. Baddour,Matthew E. Levison,Thomas J. Pallasch,Donald A. Falace,Kathryn A. Taubert +15 more
TL;DR: A new algorithm is proposed to aid clinicians in deciding which children with fever for ≥5 days and ≤4 classic criteria should undergo electrocardiography, receive intravenous gamma globulin (IVIG) treatment, or both for Kawasaki disease.
Journal ArticleDOI
Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.
Paul Monagle,Anthony K.C. Chan,Neil A. Goldenberg,Rebecca Ichord,Janna M. Journeycake,Ulrike Nowak-Göttl,Sara K. Vesely +6 more
TL;DR: The evidence supporting most recommendations for antithrombotic therapy in neonates and children remains weak and Studies addressing appropriate drug target ranges and monitoring requirements are urgently required in addition to site- and clinical situation-specific thrombosis management strategies.
Journal ArticleDOI
Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Paul Monagle,Elizabeth Chalmers,Anthony K.C. Chan,Gabrielle deVeber,Fenella J. Kirkham,Patricia Massicotte,Alan D. Michelson +6 more
TL;DR: Within this chapter, the majority of recommendations are separate for neonates and children, reflecting the significant differences in epidemiology of thrombosis and safety and efficacy of therapy in these two populations.
Journal ArticleDOI
Antithrombotic Therapy in Children
TL;DR: The following review summarizes the available information on commonly used antithrombotic agents in children, which include standard heparin, low molecular hepar in, oral anticoagulants, thrombolytic therapy, antiplatelet agents, antithromabin concentrates, and protein C concentrates.
References
More filters
Journal ArticleDOI
Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli
Diane Pennica,William E. Holmes,William J. Kohr,Richard N. Harkins,Gordon A. Vehar,Carole A. Ward,William F. Bennett,Elizabeth Mcleod Yelverton,Peter H. Seeburg,Herbert L. Heyneker,David V. Goeddel,Desire Collen +11 more
TL;DR: Bacterial clones containing human tissue-type plasminogen activator cDNA sequences were identified in a cDNA library prepared using gel-fractionated mRNA from human melanoma cells and a polypeptide was produced having the fibrinolytic properties characteristic of authentic human t-PA.
Book ChapterDOI
Parts I and II
E. P. Mazets,S. Golenetskii,V. N. Il'Inskii,V. N. Panov,R. Aptekar,Yu. A. Gur'yan,M. P. Proskura,I. A. Sokolov,Z. Ya. Sokolova,T. V. Kharitonova,A. V. Dyatchkov,N. G. Khavenson +11 more
TL;DR: In this article, the temporal structure, fluxes, energy spectra and coordinates of the sources of gamma-ray bursts detected in the KONUS experiment on Venera 11 andVenera 12 space probes were presented.
Journal ArticleDOI
Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
A. Koneti Rao,Craig M. Pratt,Andrew D. Berke,Allan Jaffe,Ira S. Ockene,Theodore L. Schreiber,William R. Bell,Genell L. Knatterud,Thomas L. Robertson,Michael L. Terrin +9 more
TL;DR: In the doses administered, rt-PA induces systemic fibrinogenolysis that is substantially less intense than that induced by streptokinase, and emphasize the need for avoidance of invasive procedures and for meticulous care in the selection and management of patients subjected to thrombolytic therapy.
Journal ArticleDOI
Thrombolytic therapy: current status (1).
Victor J. Marder,Sol Sherry +1 more
TL;DR: One decade after the Food and Drug Administration approved the plasminogen activators streptokinase and urokinase, thrombolytic therapy is no longer a novel approach to the treatment of thrombotic disease.
Journal ArticleDOI
Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism.
Marc Verstraete,Gah Miller,Henri Bounameaux,Bernard Charbonnier,J. P. Colle,G. Lecorf,G. A. Marbet,P. Mombaerts,C. G. Olsson +8 more
TL;DR: Eight centers participated in a study in which intrapulmonary and intravenous administration of recombinant tissue-type plasminogen activator (rt-PA) were compared in 34 patients with acute massive pulmonary embolism.